Novo Nordisk CagriSema Phase 3 Results: Obesity Catalyst Update
Decision brief
Answer first · skim in under a minute
Novo Nordisk’s CagriSema phase 3 update shows strong obesity and diabetes efficacy, but the obesity readout fell short of top-tier expectations. This plan focuses on the catalyst, the comparator data, and what BD teams and investors should watch next.
Novo Nordisk’s CagriSema phase 3 obesity readout from REDEFINE 1 is a clear efficacy catalyst: 22.7% mean weight loss at 68 weeks when treatment was adhered to, versus 2.3% on placebo. For investors and BD teams, the dual GLP-1/amylin mix now has peer-reviewed Phase 3 backing, with caveats on estimands and safety.
Contents11 sections
Key Takeaways
- CagriSema phase 3 REDEFINE 1 met its primary endpoint versus placebo at 68 weeks in adults with obesity or overweight without diabetes.
- Trial product estimand: 22.7% mean weight loss for CagriSema versus 2.3% placebo; treatment policy: 20.4% versus 3.0%.
- Semaglutide 2.4 mg alone reached 16.1% and cagrilintide alone 11.8% on the same adherence estimand.
- NEJM published REDEFINE 1 on June 22, 2025 (NCT05567796); gastrointestinal adverse events were common (79.6% vs 39.9% placebo).
What did CagriSema phase 3 REDEFINE 1 measure?
REDEFINE 1 was a 68-week Phase 3 efficacy and safety trial of once-weekly subcutaneous CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg) versus each component and placebo.
Novo Nordisk disclosed headline results on December 20, 2024, via GlobeNewswire. The trial enrolled people with obesity or overweight plus comorbidity, without type 2 diabetes.
How large was the weight-loss effect versus placebo?
When analyzing as if all patients adhered to treatment, CagriSema delivered 22.7% mean weight loss at week 68 versus 2.3% with placebo. Under the treatment policy estimand (effect regardless of adherence), mean loss was 20.4% versus 3.0% placebo.
NEJM later reported an estimated −20.4% change versus −3.0% placebo (difference −17.3 percentage points; 95% CI −18.1 to −16.6; P<0.001). See NEJM REDEFINE 1 and PubMed PMID 40544433.
How did CagriSema compare with each component?
On the adherence (trial product) estimand, mean weight loss at 68 weeks was:
- CagriSema: 22.7%
- Semaglutide 2.4 mg: 16.1%
- Cagrilintide 2.4 mg: 11.8%
- Placebo: 2.3%
About 40.4% of CagriSema-treated patients lost 25% or more of body weight, versus 16.2% on semaglutide alone and 0.9% on placebo. Mean baseline weight was 106.9 kg across 3,417 randomized adults.
Safety signal investors should not ignore
Gastrointestinal adverse events affected 79.6% of patients on cagrilintide–semaglutide versus 39.9% on placebo in the NEJM report. Events were mainly transient and mild to moderate, but the rate gap matters for real-world persistence and for any commercial comparison with Wegovy (semaglutide 2.4 mg).
Why the dual estimand framing matters for BD teams
REDEFINE 1 reported two estimands. The trial product (adherence) figure of 22.7% versus 2.3% placebo answers “what if everyone stayed on drug.” The treatment policy figure of 20.4% versus 3.0% answers “what happened in the randomized population.” Investors comparing CagriSema phase 3 slides should cite which estimand they use.
Component arms also help set expectations. Semaglutide 2.4 mg alone at 16.1% and cagrilintide alone at 11.8% show both pieces contribute, while the combination adds further loss on the same 68-week clock. That structure is useful when modeling incremental benefit versus Wegovy-class GLP-1 monotherapy.
Trial size, baseline weight, and publication path
The December 2024 GlobeNewswire release described 3,417 randomized adults with mean baseline body weight of 106.9 kg. NEJM later published the peer-reviewed dataset on June 22, 2025, with ClinicalTrials.gov number NCT05567796. That path—from company headline to journal—lets diligence teams verify numbers against the primary paper rather than secondary summaries.
Gastrointestinal adverse events remained the main tolerability theme: 79.6% on CagriSema versus 39.9% on placebo in the NEJM report. Most events were mild to moderate and transient, but the absolute rate gap is material for persistence models and for any payer conversation about real-world discontinuation.
What remains unproven for the CagriSema franchise
REDEFINE 1 does not by itself prove cardiovascular outcomes, long-term adherence, or superiority in type 2 diabetes with obesity. Separate REDEFINE studies cover diabetes and CV outcomes; those readouts should not be inferred from REDEFINE 1 alone. Regulatory filing timing is a company decision outside the published efficacy tables.
Related NovaPharma coverage
- Novo Nordisk company profile
- Obesity disease coverage
- Eli Lilly raises 2026 guidance on Mounjaro demand
Frequently Asked Questions
What did CagriSema phase 3 REDEFINE 1 show for weight loss?
In the trial product estimand, CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg) achieved 22.7% mean weight loss at 68 weeks versus 2.3% with placebo. Under the treatment policy estimand, mean loss was 20.4% versus 3.0% placebo.
How large was the REDEFINE 1 trial?
REDEFINE 1 randomized 3,417 adults with obesity or overweight plus at least one comorbidity and without type 2 diabetes. Mean baseline body weight was 106.9 kg. The ClinicalTrials.gov identifier is NCT05567796.
How did CagriSema compare with semaglutide alone?
On the trial product estimand at week 68, CagriSema reached 22.7% mean weight loss versus 16.1% with semaglutide 2.4 mg alone and 11.8% with cagrilintide 2.4 mg alone. About 40.4% of CagriSema patients lost 25% or more of body weight.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for CagriSema.
Unlock full calendar →Novo Nordisk pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
Deeper reading
Industry reports & whitepapers
- Ensuring Compatibility for GLP-1-based Drugs — The rise of GLP-1 agonists like Semaglutide demands innovative ready-to-use cartridges to enhance de…